CAR-T cell therapy for chronic or hard-to-treat ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 75 years old
- You have had ITP for more than 12 months (chronic) or your ITP has not improved with standard treatments (refractory)
- Your platelet count is less than 30,000 per microliter of blood
- You are not taking medications that affect platelet function (like aspirin or blood thinners) within 2 weeks of starting the study
- You are willing to use reliable birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial tests a new treatment called universal allogeneic CAR T-cell therapy (QT-019C) for adults with severe, hard-to-treat immune thrombocytopenia (ITP). It aims to see if targeting CD19 and BCMA on immune cells can safely improve platelet counts.
This study tests whether a new treatment using specially designed immune cells (CD19 CAR NK cells) can help people with immune thrombocytopenia (ITP) that has not improved with standard treatments. It aims to improve platelet counts and reduce bleeding risk.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.